Inhibition of the target of rapamycin signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies.
Researchers reported that rapamycin extended median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females. Thus, rapamycin may extend lifespan by postponing death
from cancer, by retarding mechanisms of ageing, or both.
Systemic lupus erythematosus and Sjogren's syndrome are chronic inflammatory diseases characterized by the dysfunction of T cells, B cells, and dendritic cells and the production of antinuclear autoantibodies. The mammalian target of rapamycin in T and B cells has been successfully targeted for treatment of systemic lupus erythematosus with rapamycin or sirolimus both in patients and animal models.
A study showed that rapamycin in concentrations of 1-10 nmol / l arrested the
cell cycle progression of Hl-60 cells in the G1 phase, without evident.
cytotoxic effect. At concentrations higher than 10 nmol / l, rapamycin exerted
a significant proapoptotic effect, with the collapse of mitochondrial potential
and caspase-3 activation.
Read more：http://www.acid-lactic-bacteria.com/bulk-drug/Rapamycin/
Researchers reported that rapamycin extended median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females. Thus, rapamycin may extend lifespan by postponing death
from cancer, by retarding mechanisms of ageing, or both.
Systemic lupus erythematosus and Sjogren's syndrome are chronic inflammatory diseases characterized by the dysfunction of T cells, B cells, and dendritic cells and the production of antinuclear autoantibodies. The mammalian target of rapamycin in T and B cells has been successfully targeted for treatment of systemic lupus erythematosus with rapamycin or sirolimus both in patients and animal models.
A study showed that rapamycin in concentrations of 1-10 nmol / l arrested the
cell cycle progression of Hl-60 cells in the G1 phase, without evident.
cytotoxic effect. At concentrations higher than 10 nmol / l, rapamycin exerted
a significant proapoptotic effect, with the collapse of mitochondrial potential
and caspase-3 activation.
No comments:
Post a Comment